Medical Specialty >> Gynecology
High Blood Pressure Often Mistaken for Menopausal Symptoms in Women
1:31 PM CST.
Read article
- Women More Prone to Nighttime Cardiac Arrest Than Men
- More Than 200,000 Americans Have Lupus
- Premature Menopause May Bring Tougher Symptoms for Women
- Estrogen Taken During Gender-Affirming Surgeries Won’t Raise Blood Clot Risk: Study
JOURNAL UPDATE
Respiratory, Physical, Psych Sequelae ID’d After COVID-19 Discharge
11:21 PM CST.Reduced exercise tolerance was most common symptom identified up to four months after hospital…
- Cardiovascular Disease Still Leading Cause of Death Worldwide
- Metformin Use for T2DM May Reduce COVID-19 Mortality
- Aspirin Use Tied to Longer Bladder, Breast Cancer Survival
MONTHLY JOURNAL SUMMARY
September 2020 Briefing - OBGYN & Women’s Health
October 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Immunotherapy with Checkpoint Inhibitors in Triple Negative Breast Cancer (TNBC)
Karima Oualla, MD.
Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative…
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
